[对文章的评论:“FINDRISC问卷对成人胰岛素抵抗的诊断性能”]。

Citlalli Valadez-Mayorga
{"title":"[对文章的评论:“FINDRISC问卷对成人胰岛素抵抗的诊断性能”]。","authors":"Citlalli Valadez-Mayorga","doi":"10.5281/zenodo.14616808","DOIUrl":null,"url":null,"abstract":"<p><p>The FINDRISC test is a scale developed in Finland by Lindström and Tuomilehto to determine a patient's risk of developing type 2 diabetes. This scale has been accepted and valid in many countries, including Spain, Greece, Norway, and Germany. Having widely accepted instruments opens the possibility of conducting studies between different countries or cultures, which implies evaluating the various items of the instrument in the most accurate way possible. It is important to note that in Mexico, according to ENSANUT 2022, the prevalence of diagnosed diabetes was 12.6% and that of undiagnosed diabetes was 5.8%, resulting in a total prevalence of diabetes of 18.3%. In contrast, in Finland, for the year 2021, the prevalence was 7.7%, which denotes a large difference in the number of people living with diabetes in both countries.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"63 2","pages":"e6639"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037139/pdf/","citationCount":"0","resultStr":"{\"title\":\"[Comment on the article: \\\"Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults\\\"].\",\"authors\":\"Citlalli Valadez-Mayorga\",\"doi\":\"10.5281/zenodo.14616808\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The FINDRISC test is a scale developed in Finland by Lindström and Tuomilehto to determine a patient's risk of developing type 2 diabetes. This scale has been accepted and valid in many countries, including Spain, Greece, Norway, and Germany. Having widely accepted instruments opens the possibility of conducting studies between different countries or cultures, which implies evaluating the various items of the instrument in the most accurate way possible. It is important to note that in Mexico, according to ENSANUT 2022, the prevalence of diagnosed diabetes was 12.6% and that of undiagnosed diabetes was 5.8%, resulting in a total prevalence of diabetes of 18.3%. In contrast, in Finland, for the year 2021, the prevalence was 7.7%, which denotes a large difference in the number of people living with diabetes in both countries.</p>\",\"PeriodicalId\":94200,\"journal\":{\"name\":\"Revista medica del Instituto Mexicano del Seguro Social\",\"volume\":\"63 2\",\"pages\":\"e6639\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037139/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista medica del Instituto Mexicano del Seguro Social\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5281/zenodo.14616808\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.14616808","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

FINDRISC测试是由Lindström和Tuomilehto在芬兰开发的一种量表,用于确定患者患2型糖尿病的风险。该量表已被许多国家接受并有效,包括西班牙、希腊、挪威和德国。拥有被广泛接受的仪器,就有可能在不同的国家或文化之间进行研究,这意味着以尽可能准确的方式评估仪器的各个项目。值得注意的是,根据ENSANUT 2022,在墨西哥,确诊糖尿病的患病率为12.6%,未确诊糖尿病的患病率为5.8%,导致糖尿病的总患病率为18.3%。相比之下,在芬兰,2021年的患病率为7.7%,这表明两国糖尿病患者人数存在很大差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Comment on the article: "Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults"].

The FINDRISC test is a scale developed in Finland by Lindström and Tuomilehto to determine a patient's risk of developing type 2 diabetes. This scale has been accepted and valid in many countries, including Spain, Greece, Norway, and Germany. Having widely accepted instruments opens the possibility of conducting studies between different countries or cultures, which implies evaluating the various items of the instrument in the most accurate way possible. It is important to note that in Mexico, according to ENSANUT 2022, the prevalence of diagnosed diabetes was 12.6% and that of undiagnosed diabetes was 5.8%, resulting in a total prevalence of diabetes of 18.3%. In contrast, in Finland, for the year 2021, the prevalence was 7.7%, which denotes a large difference in the number of people living with diabetes in both countries.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信